An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies
Latest Information Update: 13 Feb 2023
At a glance
- Drugs Mivavotinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Post-transplant lymphoproliferative disorder; Solid tumours; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Takeda Oncology
- 15 Jul 2021 Status changed from active, no longer recruiting to completed.
- 29 Apr 2021 Planned End Date changed from 15 Apr 2021 to 15 Jul 2021.
- 29 Apr 2021 Planned primary completion date changed from 15 Apr 2021 to 15 Jul 2021.